1502P CaboRISE (AIO-HEP-0320/ass.): A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function. - Koch, C.; Waldschmidt, D.T.; Goetze, T.O.; Ehmer, U.; Ertl, S.; Schmidt, H.; Van Bömmel, F.; Jacobasch, L.; Pink, D.; Wehler, T.C.; Roderburg, C.; Angermeier, S.; et al. (Annals of Oncology, 2025)